secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001831283-23-000079
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q1 net loss $24M; mavacamten NDA accepted in China with priority review
-------------------------------------------------------------------------------

- Net loss of $24.0M in Q1 2023 vs $27.7M in Q1 2022; cash $286.6M at March 31, 2023.
- Phase 3 EXPLORER-CN trial of mavacamten met primary endpoint in Chinese oHCM patients.
- China NMPA accepted mavacamten NDA with priority review; approved in Macau in May 2023.
- Pascal Qian promoted to Chief Commercial Officer to lead mavacamten launch preparations.
- Cash runway projected through end of 2024; key milestones for TP-03, infigratinib, BBP-398.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000079/0001831283-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000079/lian-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer